Rijnders BJA - Search Results

1

Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19.

Raadsen MP, Gharbharan A, Jordans CCE, Mykytyn AZ, Lamers MM, van den Doel PB, Endeman H, van den Akker JPC, GeurtsvanKessel CH, Koopmans MPG, Rokx C, Goeijenbier M, van Gorp ECM, Rijnders BJA, Haagmans BL. Raadsen MP, et al. Among authors: rijnders bja. J Clin Immunol. 2022 Feb;42(2):232-239. doi: 10.1007/s10875-021-01168-3. Epub 2021 Nov 12. J Clin Immunol. 2022. PMID: 34767118 Free PMC article.

2

Peginterferon alfa-2a for AIDS-associated Kaposi sarcoma: experience with 10 patients.

Rokx C, van der Ende ME, Verbon A, Rijnders BJ. Rokx C, et al. Clin Infect Dis. 2013 Nov;57(10):1497-9. doi: 10.1093/cid/cit517. Epub 2013 Aug 2. Clin Infect Dis. 2013. PMID: 23912848

3

The efficacy, pharmacokinetics, and safety of a nevirapine to rilpivirine switch in virologically suppressed HIV-1-infected patients.

Rokx C, Blonk M, Verbon A, Burger D, Rijnders BJ. Rokx C, et al. J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):36-9. doi: 10.1097/QAI.0000000000000363. J Acquir Immune Defic Syndr. 2015. PMID: 25247434 Clinical Trial.

4

Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort.

Rokx C, Fibriani A, van de Vijver DA, Verbon A, Schutten M, Gras L, Rijnders BJ; AIDS Therapy Evaluation in the Netherlands National Observational Cohort. Rokx C, et al. Clin Infect Dis. 2015 Jan 1;60(1):143-53. doi: 10.1093/cid/ciu763. Epub 2014 Oct 1. Clin Infect Dis. 2015. PMID: 25273080

5

More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort.

Rokx C, Fibriani A, van de Vijver D, Verbon A, Schutten M, Gras L, Rijnders BJ. Rokx C, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19491. doi: 10.7448/IAS.17.4.19491. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394000 Free PMC article.

6

The efficacy, pharmacokinetics, safety and cardiovascular risks of switching nevirapine to rilpivirine in HIV-1 patients: the RPV switch study.

Rokx C, Blonk M, Verbon A, Burger D, Rijnders BJ. Rokx C, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19789. doi: 10.7448/IAS.17.4.19789. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397533 Free PMC article.

7

Short communication: Lipids and cardiovascular risk after switching HIV-1 patients on nevirapine and emtricitabine/tenofovir-DF to rilpivirine/emtricitabine/tenofovir-DF.

Rokx C, Verbon A, Rijnders BJ. Rokx C, et al. AIDS Res Hum Retroviruses. 2015 Apr;31(4):363-7. doi: 10.1089/AID.2014.0278. Epub 2015 Feb 26. AIDS Res Hum Retroviruses. 2015. PMID: 25625211 Clinical Trial.

8

Evidence gathered from randomized clinical trials and observational studies on the equivalence of emtricitabine and Lamivudine.

Rokx C, Rijnders BJ. Rokx C, et al. Clin Infect Dis. 2015 Jun 1;60(11):1732-3. doi: 10.1093/cid/civ117. Epub 2015 Feb 16. Clin Infect Dis. 2015. PMID: 25690599 No abstract available.

9

How does weight influence tenofovir disoproxil-fumarate induced renal function decline?

Rokx C, Van der Ende ME, Rijnders BJ. Rokx C, et al. AIDS. 2015 Mar 13;29(5):643-5. doi: 10.1097/QAD.0000000000000577. AIDS. 2015. PMID: 25710292 No abstract available.

10

Proximal tubular dysfunction in a HIV-1 patient with coadministered tenofovir disoproxil-fumarate and ibuprofen.

Duim AR, Rokx C, van Gorp EC, Rijnders BJ. Duim AR, et al. AIDS. 2015 Mar 27;29(6):746-8. doi: 10.1097/QAD.0000000000000575. AIDS. 2015. PMID: 25849839 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

210 results

Search Page